Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
MLS-101-206
Phase 2 small_molecule completed
Quick answer
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD for Chronic Kidney Disease is a Phase 2 program (small_molecule) at Mineralys Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mineralys Therapeutics
- Indication
- Chronic Kidney Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed